faculty

Hans-Peter Kiem

hkiem@fhcrc.org

Fred Hutch, 

Developmental Biology, Stem Cells & Aging

Gene Expression, Cell Cycle & Chromosome Biology

Genetics, Genomics & Evolution

Conducting Preclinical and Clinical Studies of Gene Therapy

Faculty Contact Information

Lab Information

Location: Fred Hutchinson Cancer Research Center Building: Thomas Box: D1-100 http://labs.fhcrc.org/kiem/index.html

Accepting Students For:

Rotation, Autumn
Rotation, Spring
Rotation, Summer
Rotation, Winter
Permanent

Publications

The following publications were retrieved from PubMed:

Engineering resistance to CD33-targeted immunotherapy in normal hematopoiesis by CRISPR/Cas9-deletion of CD33 exon 2.

Humbert O, Laszlo GS, Sichel S, Ironside C, Haworth KG, Bates OM, Beddoe ME, Carrillo RR, Kiem HP, Walter RB.

Leukemia. 2018 Oct 5;

Sorting Out the Best: Enriching Hematopoietic Stem Cells for Gene Therapy and Editing.

Radtke S, Humbert O, Kiem HP.

Mol Ther. 2018 Oct 3; 10(26)2328-2329

Screening Clinical Cell Products for Replication Competent Retrovirus: The National Gene Vector Biorepository Experience.

Cornetta K, Duffy L, Feldman SA, Mackall CL, Davila ML, Curran KJ, Junghans RP, Tang JY, Kochenderfer JN, O'Cearbhaill R, Archer G, Kiem HP, Shah NN, Delbrook C, Kaplan R, Brentjens RJ, Rivière I, Sadelain M, Rosenberg SA.

Mol Ther Methods Clin Dev. 2018 Sep 21; (10)371-378

Minimal conditioning in Fanconi anemia promotes multi-lineage marrow engraftment at 10-fold lower cell doses.

Haworth KG, Ironside C, Ramirez MA, Weitz S, Beard BC, Schwartz JD, Adair JE, Kiem HP.

J Gene Med. 2018 Aug 21; e3050

Efficient Enrichment of Gene-Modified Primary T Cells via CCR5-Targeted Integration of Mutant Dihydrofolate Reductase.

Paul B, Ibarra GSR, Hubbard N, Einhaus T, Astrakhan A, Rawlings DJ, Kiem HP, Peterson CW.

Mol Ther Methods Clin Dev. 2018 Jun 15; (9)347-357

Research Summary

The Kiem Lab studies cell and gene therapy with a particular interest in the biology of blood and marrow stem cells and the development and use of novel genome editing technologies. The overall goal is to develop better stem cell transplant and cell and gene therapy treatments for patients with genetic and infectious diseases and cancer.